Tyra Biosciences (NASDAQ:TYRA) Shares Down 6% – What’s Next?

05 Jan 2026, 21:42 by Michael Walen · The Markets Daily

Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report)’s share price was down 6% during trading on Monday . The company traded as low as $25.35 and last traded at $25.1950. Approximately 357,758 shares traded hands during mid-day trading, a decline of 27% from the average daily volume of 491,391 shares. The stock had previously closed at $26.79.

Analysts Set New Price Targets

TYRA has been the topic of a number of research analyst reports. Wall Street Zen raised Tyra Biosciences from a “sell” rating to a “hold” rating in a report on Sunday. Oppenheimer reaffirmed an “outperform” rating and set a $36.00 target price on shares of Tyra Biosciences in a research report on Wednesday, September 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday, October 8th. Finally, Wedbush raised their price target on shares of Tyra Biosciences from $30.00 to $37.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Tyra Biosciences presently has an average rating of “Moderate Buy” and an average price target of $33.17.

Get Our Latest Stock Analysis on Tyra Biosciences

Tyra Biosciences Stock Down 1.9%

The stock has a market cap of $1.40 billion, a price-to-earnings ratio of -14.06 and a beta of 1.07. The company’s 50-day moving average is $20.47 and its 200-day moving average is $14.83.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). On average, research analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Insider Activity

In other news, Director Robert J. More sold 246,871 shares of the business’s stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $20.25, for a total value of $4,999,137.75. Following the transaction, the director directly owned 3,833,425 shares of the company’s stock, valued at $77,626,856.25. The trade was a 6.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 15.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Federated Hermes Inc. grew its stake in shares of Tyra Biosciences by 586.3% during the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after purchasing an additional 1,841 shares during the last quarter. SG Americas Securities LLC bought a new position in Tyra Biosciences in the 3rd quarter valued at $133,000. Russell Investments Group Ltd. boosted its position in Tyra Biosciences by 27.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock valued at $178,000 after buying an additional 2,766 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Tyra Biosciences by 14.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after buying an additional 1,668 shares during the period. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Tyra Biosciences during the second quarter worth $177,000. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Company Profile

(Get Free Report)

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.